Binding of these two proteins results in degradation of PARP-1 and cell cycle arrest in prophase, an effect stimulated by the microtubule inhibitor docetaxel resulting in resistance to this drug in CHFR-over-expressing cancer cells. The gene discussed is PARP1; the disease is cancer.